The guidance is part of the broader FDA Drug Competition Action Plan that was introduced in June 2017 with the
intent of increasing competition in the drug marketplace and facilitating entry into the market for lower-cost
Read more: https://www.heartland.org/news-opinion/news/fda-issues-guidance-to-speed-approval-of-complex-transdermal-drugs
A disruptive market of $410 billion until 2023, changes dramatically with the entrance of small and medium size
players, many of them rising up from the startup community.
Read more :https://www.forbes.com/sites/yiannismouratidis/2018/12/09/the-rise-of-use-of-medical-devices-force-fda-to-change-the-rules/#766e061c2101
The FDA has issued an update to its 2015 draft guidance on developing drugs to treat rare diseases. The new
draft guidance, issued last month by the Center for Drug Evaluation and Research and the Center for Biologics
Evaluation and Research within the FDA, contains several updates to the original document
Read more at: https://www.ajmc.com/newsroom/fda-revises-draft-guidance-on-developing-drugs-for-rare-diseases
The United States Food and Drug Administration (FDA) set a record this year in new drug approvals, giving green
light to multiple innovative drugs to fight cancers and HIV.
Read more at: http://www.china.org.cn/world/Off_the_Wire/2018-12/31/content_74328075.htm
Since becoming Commissioner of the Food and Drug Administration (FDA) in 2017, Dr Scott Gottlieb has
Read more at: https://www.thepharmaletter.com/article/looking-ahead-fda-priorities-for-2019